GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics
GSK and CAMP4 Therapeutics have entered a strategic research, collaboration and license agreement focused on RNA-based therapeutics for neurodegenerative and kidney (renal) diseases.13
The collaboration will leverage CAMP4’s proprietary RAP Platform to identify regulatory RNAs (regRNAs) that control expression of multiple gene targets and to generate regRNA‑targeting antisense oligonucleotide (ASO) candidates that boost target gene expression.13
Under the agreement, CAMP4 receives a $17.5 million upfront cash payment from GSK.124
CAMP4 is eligible for additional development and commercial milestone payments as well as tiered royalties on any future product sales arising from the collaboration.124
CAMP4 will be responsible for discovery-stage work, including identifying regRNAs and creating ASO candidates, while GSK will lead further development and commercialization of any resulting drug candidates.134
The scientific goal is to upregulate (amplify) expression of validated genetic targets implicated in disease, addressing conditions driven by under-expression of healthy protein in neurodegenerative and kidney disorders.13
GSK executives highlighted that the partnership combines CAMP4’s RNA discovery and gene-activity–increasing platform with GSK’s expertise in therapeutic oligonucleotides, human genetics, and advanced lab and data technologies to develop novel medicines.124
CAMP4 positions its regRNA‑targeting ASO approach as a disease-modifying strategy for genetic diseases where boosting remaining functional gene activity could restore healthier protein levels.13
Sources:
1. https://www.globenewswire.com/news-release/2025/12/18/3207552/0/en/CAMP4-and-GSK-Enter-Strategic-Collaboration-to-Advance-RNA-Based-Therapeutic-Discoveries.html
2. https://markets.financialcontent.com/wral/article/gnwcq-2025-12-18-camp4-and-gsk-enter-strategic-collaboration-to-advance-rna-based-therapeutic-discoveries
3. https://www.fiercebiotech.com/biotech/gsk-pays-175m-pitch-its-tent-camp4-regulatory-rna-deal
4. https://www.stocktitan.net/news/CAMP/camp4-and-gsk-enter-strategic-collaboration-to-advance-rna-based-4fyqs8rwrvlh.html